Merck Sharp + Dohme Corp.

Agency for Science, Technology and Research

Msd International Gmbh (singapore Branch)

Michael B Garrigou

Tomi K Sawyer

Nicolas Cedric Boyer

Sookhee Nicole Ha

Chunhui Huang

Charles William Johannes

Tsz Ying Yuen

Pietro Aronica

Srinivasaraghavan Kannan

Anthony W Partridge

The invention provides compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (K-Ras) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Macrocyclic peptides as potent inhibitors of K-RAS G12D mutant

Growing community of inventors

Newton, MA, United States of America

Michael B Garrigou